4-FA
4-fluoroamphetamine
1Provenance card
the boundary, as counts
Sources
3228 with DOI
16 strong · 10 moderate · 6 weak
Compilations
12026-04-26T17:01:23.687Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
34last ruled 2026-10-02
0 awaiting a ruling
Issued documents
42026-10-02T12:19:20.238Z
notice · info card · emergency
Searches
161 with no results
queries and counts on the build
Claims checked
9892 supported
92 supported · 6 not
Correspondence
0received
consent field ships in Phase 4
Edges
295
derivations recorded for this entity
Complete over 32 sources, 1 compilation, and 34 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/4-fa/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-02issueIssued info_card
- 2026-10-02srcPharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion
- 2026-10-02srcAnalysis of 4-fluoroamphetamine in cerumen after controlled oral application
- 2026-10-02srcPrevalence and concentrations of new designer stimulants, synthetic opioids, benzodiazepines, and hallucinogens in postmortem hair samples: A 13-year retrospective study
- 2026-10-02src4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: A retrospective analysis
- 2026-10-02srcIndependent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4-fluoroamphetamine intoxication
- 2026-10-02srcDesigner drugs: mechanism of action and adverse effects
- 2026-10-02srcDrug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine
- 2026-10-02srcHaemorrhagic stroke related to the use of 4-fluoroamphetamine
- 2026-10-02srcFatalities, Cerebral Hemorrhage, and Severe Cardiovascular Toxicity After Exposure to the New Psychoactive Substance 4-Fluoroamphetamine: A Prospective Cohort Study
- 2026-10-02srcMonitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre
- 2026-10-02srcPharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans
- 2026-10-02srcMonoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones
- 2026-10-02srcExcretion of 4-fluoroamphetamine and three metabolites in urine after controlled oral ingestion
- 2026-10-02srcNeurotoxicity screening of (illicit) drugs using novel methods for analysis of microelectrode array (MEA) recordings
- 2026-10-02srcDifferential effects of psychoactive substances on human wildtype and polymorphic T356M dopamine transporters (DAT)
- 2026-10-02srcAcute onset heart failure due to reverse type Takotsubo cardiomyopathy caused by a single dose of 4-Fluoroamphetamine in a healthy young individual
- 2026-10-02srcCardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings
- 2026-10-02srcA First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State
- 2026-10-02srcTakotsubo cardiomyopathy as a consequence of 4-fluoroamphetamine Mono-intoxication documented by toxicological analyses
- 2026-10-02srcMonoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics
- 2026-10-02srcFatal Intoxications from a Combination of 4-Fluoroamphetamine and 25C-NBOMe
- 2026-10-02srcNovel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review
- 2026-10-02src4-Fluoroamphetamine in the Netherlands: more than a one-night stand
- 2026-10-02srcPurity, adulteration and price of drugs bought on-line versus off-line in the Netherlands
- 2026-10-02srcIn vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat
- 2026-10-02srcSafety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans
- 2026-10-02srcPara-Halogenation Affects Monoamine Transporter Inhibition Properties and Hepatocellular Toxicity of Amphetamines and Methcathinones
- 2026-10-02srcPara-Halogenation of Amphetamine and Methcathinone Increases the Mitochondrial Toxicity in Undifferentiated and Differentiated SH-SY5Y Cells
- 2026-10-02srcRelationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs
- 2026-10-02srcLegal Status of 4-Fluoroamphetamine by Jurisdiction
- 2026-10-02srcSchedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I
- 2026-10-02srcPubChem Compound Summary: 4-Fluoroamphetamine (CID 9986)
- 2026-10-02publicationPublication — publishagent-psx
- 2026-10-02revisionr1.a1
- 2026-10-02rulingRuling — psx:substance/4-fa/proposal/article_section_proposals/088072c4-8aff-447a-a48a-4f74ee69addbfounder
- 2026-10-02rulingRuling — psx:substance/4-fa/proposal/article_section_proposals/5108f818-93be-48fd-92cc-ad87568c6842founder
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-06-04proposal28 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-04-26revisionRevision 1
- 2026-04-26absenceSearched ClinicalTrials.gov for "4-fluoroamphetamine" — no results
- 2026-04-26genGeneration — pipeline-v5 · with 1 morepipeline-v5
- 2026-04-26rungeneration run
The same entries, as forms: six forms.